One of the largest concussion studies ever conducted found that a new blood test developed by Abbott was able to detect a protein in the blood that confirmed a concussion, even if the result of a CT scan came back negative.

GlaxoSmithKline said an experimental multiple myeloma treatment showed a meaningful response in patients that have run out of three previous treatment options.

Older adults who cut back on the amount of vegetable protein in their diets may be more likely to experience age-related health problems than their peers who increase the amount of plant protein they eat, a Spanish study suggests.

A combination of AstraZeneca’s lung cancer drug Imfinzi and an experimental treatment failed to extend the lives of patients with advanced non-small cell lung cancer (NSCLC) and high levels of gene mutations

Rockville, Maryland-based RegenxBio entered a license deal with Pfizer for a gene therapy for Friedreich’s ataxia, the most common hereditary ataxia.

Mallinckrodt plc and Silence Therapeutics plc announced a collaboration that will allow the companies to develop and commercialize RNAi drug targets designed to inhibit or ‘silence’ the complement cascade, a group of proteins that are involved in the immune system and that play a role in the development of inflammation.

U.S. regulators should continue to recommend soy protein as part of a heart-healthy diet because it helps lower cholesterol, researchers conclude from an analysis of dozens of studies done in the past two decades.

In a deal-making morning for South San Francisco-based Genentech, the Roche subsidiary struck three separate transactions with small companies to boost drug development.

The U.S. FDA approved Symdeko (tezacaftor/ivacaftor and ivacaftor) for use in children with cystic fibrosis ages 6 through 11 years who have two copies of the F508del-CFTR mutation or who have at least one mutation in the cystic fibrosis transmembrane conductance regulator gene that is responsive to the Vertex Pharmaceuticals Inc. medicine.

Researchers at the RIKEN Center for Brain Science identified a new protein that might make the connection between amyloid plaques and tau in Alzheimer’s patients.